The Lancet Haematology · 2018 · 292 citations · 20 references
PharmacyHematologyImmunologyClinical ImmunologyImmunoregulationImmunotherapyCancer ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event ManagementImmune-related Adverse EventsImmunosuppressionPharmacodynamics Of ImmunotherapiesHematologic Adverse EventsImmune-mediated Adverse EventsImmune-related Adverse Event AssessmentImmune-related Adverse Event GradingPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 Targeting
20
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider et al. · Journal of Clinical Oncology · 2018 · 3.7K citations · Full text
Life Sciences, Immunology, Oncology +17